Vortioxetine hydrobromide is under clinical development by H. Lundbeck and currently in Phase II for Bipolar Disorder (Manic Depression). According to GlobalData, Phase II drugs for Bipolar Disorder (Manic Depression) have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vortioxetine hydrobromide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Vortioxetine Hydrobromide in Bipolar Disorder (Manic Depression)

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vortioxetine hydrobromide overview

Vortioxetine hydrobromide(Brintellix, Trintellix, Vurtuoso) is a multi-modal antidepressant. It is formulated as a tablet, film-coated tablets, and drops solution for the oral route of administration. It is also administered through intravenous and sublingual route. It is indicated for the treatment of major depressive disorder.
The drug candidate is under development for the treatment of major depressive disorder in paediatric patients, bipolar depression and burning mouth syndrome. The drug candidate was under development for the treatment of generalized anxiety disorder, attention deficit hyperactivity disorder(ADHD), major depressive disorder and treatment-emergent sexual dysfunction(TESD).

See Also:

H. Lundbeck overview

H. Lundbeck (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company’s products are indicated for the treatment of Alzheimer’s disease, migraine, depression, Parkinson’s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, depression, anxiety, psychosis, and epilepsy, among others. It operates production facilities in Denmark, Italy, and France, and research centers in the US and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies, and hospitals in Italy, China, Spain, Canada, France, South Korea, Australia, the US and other countries. Lundbeck is headquartered in Valby, Denmark.

For a complete picture of Vortioxetine hydrobromide’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.